All In Biotech

Drug Trial Radar · NCT00021814

Medical Therapy of Prostatic Symptoms

Last checked: Nov 19, 2026Latest source record: Sep 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,407

Actual

Start

Dec 1995

Primary completion

Nov 30, 2001

Study completion Nov 30, 2001

Sponsor

Sponsor type
NIH
Collaborators
George Washington University
First posted
Aug 6, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The Medical Therapy of Prostatic Symptoms (MTOPS) is a clinical research study sponsored by the National Institutes of Health (NIH). The study will test whether the oral drugs finasteride (Proscar) and doxazosin (Cardura), alone or together, can delay or prevent further worsening of symptoms in men with Benign Prostatic Hyperplasia (BPH). MTOPS is the largest and longest study to simultaneously test whether these drugs can delay or prevent the clinical progression (symptom worsening) of BPH. Seventeen U.S. medical centers recruited 2,931 men diagnosed with symptomatic BPH between December 1995 and March 1998. Study doctors will continue to follow these men through November 2001 on a quarterly basis. In addition to the clinical progression of BPH, MTOPS will include evaluations of prostate volume by ultrasound, prostate biopsies among a subgroup of volunteers, and quality of life.

Conditions

  • Prostatic Hyperplasia
  • Prostatic Hypertrophy, Benign

Interventions

  • DoxazosinDrug

  • FinasterideDrug

  • Doxazosin placeboDrug

  • Finasteride placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of California

    La Jolla, California

  • Univ of Colorado Health Sciences Center

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Walter Reed Army Medical Center

    Washington D.C., District of Columbia

  • Emory University

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Iowa Hospitals Clinics

    Iowa City, Iowa

  • University of Maryland

    Baltimore, Maryland

  • Henry Ford Health Systems

    Detroit, Michigan

  • Mayo Foundation

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • New York University School of Medicine

    New York, New York

  • Columbia Presbyterian Medical Center

    New York, New York

  • Vanderbilt University

    Nashville, Tennessee

  • UT Southwestern Medical Center

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Brooke Army Medical Center

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.